Is There Value In Cytokinetics Following Its 60% Drop?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 25, 10:50AM CDT
Big money can be made in owning promising pipelines, but only if trial data validates the hope. In the case of Cytokinetics , hope was dashed when the company reported its drug for ALS, also known as Lou Gehrig's Disease, failed to meet its primary...
3 Drugs Johnson & Johnson’s Investors Better Know About
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Johnson & Johnson's sales grew 3.5% during the past year, but only because of big sales growth from a handful of its recently launched drugs. Among these fast-growing new drugs are Johnson's next-generation treatment for diabetes, a new...
Medivation Signs Deal with OncoFusion Therapeutics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 5:24PM CDT
Medivation, Inc. (MDVN) entered into a research and license agreement with OncoFusion Therapeutics, Inc
How Big Is the Threat to This Johnson & Johnson Blockbuster?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
Johnson & Johnson has been one of the most successful big drug companies over the past three years. Despite an industry-wide sales drag caused by patent expiration on top-selling drugs, Johnson has skirted the headwind thanks to a wave of...
Legal Settlement for Astellas Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:41AM CDT
Astellas Pharma announced that it has reached an agreement with the U.S. DOJ to resolve civil claims regarding the marketing of Mycamine for injection
Tetraphase Slumps: TTPH Falls 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:49AM CDT
Tetraphase Pharmaceuticals saw a big move last session, as the company’s shares fell by over 10% on the day
AVEO-Biodesix Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:00PM CDT
AVEO Pharma entered into an agreement with Biodesix to develop and commercialize ficlatuzumab with VeriStrat.
PharmAthene (PIP) Crumbles: Stock Falls by 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
PharmAthene saw a big move last session, as the company’s shares fell by over 7% on the day
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
Why I Bought Exelixis
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 04, 11:05AM CDT
Some days as a biotech investor, no matter how savvy you think you are, you just have to bury your head in the sand because you're bound to experience a bad day. That's what happened last week to shareholders of Exelixis , a company I've been very...
ARIAD Candidate in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:10PM CDT
ARIAD started phase II pivotal study on AP26113 for non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer's Xalkori (crizotinib).
AstraZeneca's Forxiga Approved in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 3:45PM CDT
AstraZeneca announced that its type II diabetes drug, Forxiga, has been approved by the Japanese Ministry of Health, Labour and Welfare.
Japan Approves Medivation/Astellas' Xtandi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 12:50PM CDT
Prostate cancer treatment, Xtandi, which is already approved in more than 35 countries is now approved in Japan.
AVEO Regains AV-203 Rights from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 5:10PM CDT
AVEO Oncology (AVEO) recently announced that it has regained worldwide rights of candidate AV-203 from Biogen Idec (BIIB).
Medivation, Inc: Fast Growing Drugs That May Become Blockbusters
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 21, 1:30PM CDT
Blockbuster status -- the gold medal term awarded to therapies racking up sales of more than $1 billion per year -- is the Holy Grail for drug developers. Arguably, it's the chance to discover blockbusters that fuels industry R&D spend and...
Medivation-Astellas Seek Xtandi Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 3:20PM CDT
The companies are looking to get Xtandi approved for the chemo-naive patient population.
AVEO Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 8:10AM CDT
AVEO Pharmaceuticals reported a fourth quarter 2013 loss of 32 cents per share.
Was Medivation's Quarter a Disaster?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 03, 5:30PM CST
Medivation's sell-off last week reflects investor disappointment in guidance for sales of Xtandi, a prostate cancer drug prescribed to patients who fail to respond to chemotherapy. Sales of Xtandi jumped double digit percentages...
Medivation Swings to Earnings in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:30AM CST
Xtandi's approval in the pre-chemo setting would boost sales significantly.
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.